Trial Search Results

A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma

The purpose of the study is to determine the efficacy and safety of enzastaurin in patients with CTCL who failed prior therapies.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Eli Lilly and Company

Stanford Investigator(s):


  • Drug: Enzastaurin


Phase 2


Inclusion Criteria:

   - Histologically confirmed mycosis fungoides or Sezary Syndrome

   - Stage IB to IVB disease at screening

   - Recurrent or refractory disease after at least 1 prior systemic therapy

   - Have adequate organ function defined as:

   - At least 30 days must have passed since other treatment for CTCL.

Exclusion Criteria:

   - Receiving concurrent treatment for CTCL

   - Unable to swallow tablets

   - Receiving high potency oral or topical steroids. Low potency oral steroid may be
   permitted in patients who have been on a stable dose for at least 4 weeks prior to
   screening. Oral or topical antihistamine is allowed.

   - Unable to discontinue use of carbamazepine, phenobarbital, or phenytoin

   - Have a serious concomitant systemic disorder or HIV

   - Have a serious cardiac condition such as myocardial infarction within past 6 months,
   angina, or heart disease as defined by the New York Heart Association (NYHA) Class III
   or IV

   - Have ECG abnormalities,

   - Are pregnant or breastfeeding

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Natalie Viakhireva
Not Recruiting